Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor
Language English Country Italy Media print-electronic
Document type Clinical Trial, Letter, Research Support, Non-U.S. Gov't
Grant support
Wellcome Trust - United Kingdom
IA/M/12/1/500261
DBT-Wellcome Trust India Alliance - India
PubMed
30213832
PubMed Central
PMC6312020
DOI
10.3324/haematol.2018.199422
PII: haematol.2018.199422
Knihovny.cz E-resources
- Keywords
- Philadelphia chromosome, acute lymphoblastic leukemia (ALL), pre-tyrosine kinase inhibitors (TKIs),
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis drug therapy mortality MeSH
- Child MeSH
- Philadelphia Chromosome * MeSH
- Imatinib Mesylate administration & dosage MeSH
- Infant MeSH
- Humans MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Follow-Up Studies MeSH
- Leukocyte Count MeSH
- Child, Preschool MeSH
- Disease-Free Survival MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Letter MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Imatinib Mesylate MeSH
Chilean National Pediatric Oncology Group PINDA Hospital Roberto del Rio Santiago Chile
Department of Pediatric Hematology and Oncology Justus Liebig University Giessen Germany
Department of Pediatric Oncology Skane University Hospital Lund Sweden
EsPhALL Trial Data Center School of Medicine and Surgery University of Milano Bicocca Monza Italy
Great Ormond Street Hospital for Children London UK
Pediatric Department University of Milano Bicocca Fondazione MBBM San Gerardo Hospital Monza Italy
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
The Chinese University of Hong Kong China
University Hospital Motol Department of Pediatric Hematology and Oncology Prague Czech Republic
University Medical Center Christian Albrechts University Kiel Germany
University Medical Center Eppendorf Clinic of Pediatric Hematology and Oncology Hamburg Germany
See more in PubMed
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354(2):166–178. PubMed
Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000;14(12):2205–2222. PubMed
Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000; 342(14):998–1006. PubMed
Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010; 28(31):4755–4761. PubMed PMC
Schultz KR, Pullen DJ, Sather HN, et al. Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2007; 109(3):926–935. PubMed PMC
Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood. 1987; 70(4):948–953. PubMed
Schrappe M, Aricò M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998; 92(8):2730–2741. PubMed
Burke MJ, Cao Q, Trotz B, et al. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009; 53(7):1289–1294. PubMed
Schrappe M, Nachman J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000) Leukemia. 2010; 24(2):253–254. PubMed
Bleckmann K, Schrappe M. Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. Br J Haematol. 2016; 172(6):855–869. PubMed
Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175–5181. PubMed PMC
Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–1471. PubMed PMC
Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306–2314. PubMed PMC
Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936–945. PubMed PMC
Cazzaniga G, De Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European inter-group study of post-induction treatment of Philadelphia-chromosome- positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018; 103(1):107–115. PubMed PMC
